Mesoblast (MESO) Competitors $15.86 +0.67 (+4.41%) Closing price 04:00 PM EasternExtended Trading$15.88 +0.02 (+0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MESO vs. ROIV, GRFS, LEGN, ELAN, RVMD, RYTM, NUVL, TGTX, AXSM, and LNTHShould you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Nuvalent (NUVL), TG Therapeutics (TGTX), Axsome Therapeutics (AXSM), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Mesoblast vs. Its Competitors Roivant Sciences Grifols Legend Biotech Elanco Animal Health Revolution Medicines Rhythm Pharmaceuticals Nuvalent TG Therapeutics Axsome Therapeutics Lantheus Roivant Sciences (NASDAQ:ROIV) and Mesoblast (NASDAQ:MESO) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment. Is ROIV or MESO more profitable? Mesoblast has a net margin of 0.00% compared to Roivant Sciences' net margin of -2,111.79%. Mesoblast's return on equity of 0.00% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-2,111.79% -15.90% -14.95% Mesoblast N/A N/A N/A Which has more volatility & risk, ROIV or MESO? Roivant Sciences has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500. Does the media prefer ROIV or MESO? In the previous week, Roivant Sciences had 3 more articles in the media than Mesoblast. MarketBeat recorded 10 mentions for Roivant Sciences and 7 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.99 beat Roivant Sciences' score of -0.08 indicating that Mesoblast is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Mesoblast 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, ROIV or MESO? Mesoblast has lower revenue, but higher earnings than Roivant Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$23.23M343.81-$171.98M-$0.70-16.79Mesoblast$5.90M344.08-$87.96MN/AN/A Do insiders & institutionals hold more shares of ROIV or MESO? 64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts recommend ROIV or MESO? Roivant Sciences presently has a consensus target price of $16.50, suggesting a potential upside of 40.43%. Mesoblast has a consensus target price of $18.00, suggesting a potential upside of 13.49%. Given Roivant Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Roivant Sciences is more favorable than Mesoblast.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25Mesoblast 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20 SummaryMesoblast beats Roivant Sciences on 9 of the 14 factors compared between the two stocks. Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MESO vs. The Competition Export to ExcelMetricMesoblastMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.03B$3.08B$5.60B$9.83BDividend YieldN/A2.27%4.60%4.11%P/E RatioN/A20.6030.3025.73Price / Sales344.08324.21448.5696.46Price / CashN/A42.0537.7558.93Price / Book3.777.588.456.01Net Income-$87.96M-$54.65M$3.25B$264.94M7 Day Performance3.73%5.38%4.01%2.77%1 Month Performance41.99%6.73%4.23%1.61%1 Year Performance145.13%31.75%36.26%29.31% Mesoblast Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MESOMesoblast2.4232 of 5 stars$15.86+4.4%$18.00+13.5%+140.7%$2.03B$5.90M0.0080Gap UpROIVRoivant Sciences2.7185 of 5 stars$11.51+1.8%$16.50+43.4%+5.3%$7.69B$29.05M0.00860GRFSGrifols3.7843 of 5 stars$10.72-0.6%$10.30-3.9%+54.4%$7.41B$7.81B0.0023,822Short Interest ↑LEGNLegend Biotech3.7378 of 5 stars$38.45-0.9%$73.33+90.7%-35.3%$7.13B$627.24M0.002,609News CoverageEarnings ReportAnalyst ForecastELANElanco Animal Health2.8671 of 5 stars$14.07+2.1%$16.17+14.9%+27.9%$6.85B$4.44B14.679,000Earnings ReportAnalyst ForecastAnalyst RevisionRVMDRevolution Medicines3.729 of 5 stars$37.18+1.5%$68.91+85.3%-16.2%$6.82B$11.58M0.00250Analyst RevisionRYTMRhythm Pharmaceuticals3.7635 of 5 stars$90.24+2.2%$91.93+1.9%+112.9%$5.62B$130.13M0.00140News CoverageInsider TradeAnalyst RevisionNUVLNuvalent2.9291 of 5 stars$78.35+0.8%$119.60+52.6%+9.5%$5.58BN/A0.0040Earnings ReportAnalyst RevisionTGTXTG Therapeutics4.3406 of 5 stars$28.72-18.0%$43.80+52.5%+31.3%$5.56B$329M145.92290High Trading VolumeAXSMAxsome Therapeutics4.721 of 5 stars$106.54+3.4%$172.33+61.8%+28.9%$5.07B$385.69M0.00380LNTHLantheus4.7098 of 5 stars$71.46+1.3%$131.20+83.6%-44.8%$4.88B$1.53B12.32700Analyst Forecast Related Companies and Tools Related Companies ROIV Competitors GRFS Competitors LEGN Competitors ELAN Competitors RVMD Competitors RYTM Competitors NUVL Competitors TGTX Competitors AXSM Competitors LNTH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MESO) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access